CryoLife, headquartered in Georgia, is a leader in the processing and distribution of human tissues for use in cardiac and vascular surgeries. CryoLife using its proprietary SynerGraft® technology processes the CryoValve® SG pulmonary heart valve and CryoPatch® SG pulmonary cardiac patch. CryoLife’s BioGlue® Surgical Adhesive is approved in the U.S. for use as an adjunct to sutures and staples to help control bleeding, CE marked in the European Community, approved in Canada and Australia for use in soft tissue repair, and in Japan for use in the repair of aortic dissections. CryoLife’s CardioGenesis specializes in the treatment of severe angina using a laser console system and fiber-optic handpieces to perform a surgical procedure known as Transmyocardial Revascularization (TMR). CryoLife markets the HeRO® Graft, which provides vascular access for hemodialysis patients. CryoLife distributes PerClot®, an absorbable powdered hemostat, in international markets. CryoLife’s BioFoam® Surgical Matrix is CE marked in the European Community for use as an adjunct to hemostasis.
Kennesaw, US
540 (est)+39%

Key People at CryoLife

Thomas F. Ackerman

Thomas F. Ackerman

Thomas F. Ackerman Executive Vice President and CFO
Steven G. Anderson

Steven G. Anderson

Chairman, President and CEO

CryoLife Locations

Kennesaw, US
Guildford, GB
Singapore, SG

CryoLife Metrics

CryoLife Summary

Founding Date


Market capitalization

$583 M

Closing share price


CryoLife Market Value History

CryoLife Online Presence

CryoLife Company Life